VEGFR/PDGFR axis modulation established second-line standards, while molecularly stratified immune combinations demonstrated tumor niche reprogramming efficacy (Bruix et al., 2017; Kudo et al., 2018; Llovet et al., 2021). The gene discussed is PDGFRB; the disease is neoplasm.